
Galapagos Investor Relations Material
Latest events

Q1 2025
Galapagos
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Galapagos NV
Access all reports
Segment Data
Access more data
Net revenue by
Source
Collaboration revenues
Product net sales
Expenses by
Financials
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises four Phase 2 programs, three Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Key slides for Galapagos NV


Q2 2024
Galapagos NV


Q4 2024
Galapagos NV
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
GLPG
Country
🇳🇱 Netherlands